- Home
- NSTS vs ACET Comparison
NSTS vs ACET Comparison
Compare NSTS & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NSTS | ACET |
|---|---|---|
| Founded | 1921 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.7M | 93.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NSTS | ACET |
|---|---|---|
| Price | $11.71 | $0.54 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 5.8K | ★ 1.9M |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,762,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 57.78 | N/A |
| 52 Week Low | $10.72 | $0.45 |
| 52 Week High | $13.32 | $1.12 |
Technical Indicators
Market Signals| Indicator | NSTS | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 66.38 | 35.46 |
| Support Level | $11.14 | $0.50 |
| Resistance Level | $11.75 | $0.57 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 94.00 | 19.25 |
Price Performance
Historical ComparisonAbout NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.